JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX) Files An 8-K Other Events

Item 8.01 Other Events.

On April6, 2017, Jaguar Animal Health,Inc. (Jaguar) and Napo
Pharmaceuticals,Inc. (Napo) issued a press release announcing
commercial updates relating to the sales and marketing of Neonorm
Calf, Neonorm Foal, and Mytesi.

A copy of the press release is attached hereto as Exhibit99.1 and
incorporated by reference herein.

Disclaimer on Forward-looking Statements

This Current Report on Form8-K, including the press release,
contains forward-looking statements within the meaning of section
27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. These include statements
regarding Napos and Jaguars estimate that the potential U.S.
market for Mytesi is approximately $100 million in gross annual
sales, Napos and Jaguars forecast that Mytesi will generate
approximately $7.0 million in net sales in 2017, with the
greatest impact on prescription growth coincident with the
deployment of the sales force and sampling program, Jaguars
expectation that Canalevia for the indication of CID in dogs will
be Jaguars first drug product candidate available commercially,
and that, pending FDA approval of Canalevia for CID, Jaguar
expects to conduct the commercial launch of Canalevia for this
indication in the next year, the structure, timing and completion
of the proposed merger and Napo debt settlement, expectations
regarding the capitalization, resources and ownership structure
of the combined company, the expectation that the merger
conditions to closing will be satisfied, Jaguars intention to
develop species-specific formulations of Neonorm in additional
target species, and Jaguars plan to develop formulations of
Canalevia for cats, horses and dogs. In some cases, you can
identify forward-looking statements by terms such as may, will,
should, expect, plan, aim, anticipate, could, intend, target,
project, contemplate, believe, estimate, predict, potential or
continue or the negative of these terms or other similar
expressions. The forward-looking statements in this release are
only predictions. Jaguar has based these forward-looking
statements largely on its current expectations and projections
about future events. These forward-looking statements speak only
as of the date of this release and are subject to a number of
risks, uncertainties and assumptions, some of which cannot be
predicted or quantified and some of which are beyond Jaguars
control. Except as required by applicable law, Jaguar does not
plan to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.

Important Information for Investors and
Stockholders

This communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation
of any vote or approval, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. In connection
with the proposed merger between Jaguar and Napo, Jaguar will
file with the Securities and Exchange Commission (the SEC) a
registration statement on FormS-4 that will include a joint proxy
statement of Jaguar and Napo that also constitutes a prospectus
of Jaguar. The definitive joint proxy statement/prospectus will
be delivered to Jaguars and Napos stockholders. INVESTORS AND
SECURITY HOLDERS OF JAGUAR AND NAPO ARE URGED TO READ THE
DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS
THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY
WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Investors and security holders will be able to
obtain free copies of the registration statement and the
definitive joint proxy statement/prospectus (when available) and
other documents filed with the SEC by Jaguar through the website
maintained by the SEC at http://www.sec.gov. Copies of the
documents filed with the SEC by Jaguar will be available free of
charge on Jaguars internet website at www.jaguaranimalhealth.com
or by contacting Jaguar at: Investor Relations, Jaguar Animal
Health,Inc., 201 Mission Street, Suite2375, San Francisco,
California, 94105; (415)-371-8300.

Participants in the Merger Solicitation

Jaguar, Napo, their respective directors and certain of their
executive officers and employees may be considered participants
in the solicitation of proxies in connection with the proposed
transaction. Information regarding the persons who may, under the
rulesof the SEC, be deemed participants in the solicitation of
Jaguars and Napos stockholders in connection with the proposed
merger will be set forth in the joint proxy statement/prospectus
when it is filed with the SEC. Information about the directors
and executive officers of Jaguar is set forth in its proxy
statement for its 2016 annual meeting of stockholders, which was
filed with the SEC on April29, 2016. Information about the
executive officers of Napo is set forth at www.napopharma.com.
Additional information regarding the participants in the proxy
solicitations and a description of their direct and indirect
interests, by security holdings or otherwise, will be contained
in the joint proxy statement/prospectus filed with the
above-referenced registration statement on FormS-4 and other
relevant materials to be filed with the SEC when they become
available.

Item9.01 Financial Statements and
Exhibits

(d) Exhibits

About JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX)

Jaguar Animal Health, Inc. is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products to address needs in animal health. As of December 31, 2016, its pipeline includes prescription drug product candidates for nine indications across multiple species, and non-prescription products targeting seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Equilevia, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm.

JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) Recent Trading Information

JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) closed its last trading session 00.000 at 0.912 with 232,894 shares trading hands.